Pinnacle Holdings LLC Makes New Investment in The Chemours Company $CC

Pinnacle Holdings LLC acquired a new stake in The Chemours Company (NYSE:CC) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 79,337 shares of the specialty chemicals company’s stock, valued at approximately $1,628,000.

A number of other hedge funds have also recently bought and sold shares of CC. Baird Financial Group Inc. acquired a new stake in Chemours during the first quarter worth approximately $148,000. Royal Bank of Canada raised its holdings in Chemours by 6.8% in the 1st quarter. Royal Bank of Canada now owns 585,702 shares of the specialty chemicals company’s stock valued at $7,926,000 after acquiring an additional 37,382 shares during the last quarter. AQR Capital Management LLC purchased a new position in shares of Chemours during the 1st quarter worth $161,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Chemours by 149.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,243 shares of the specialty chemicals company’s stock worth $593,000 after purchasing an additional 25,899 shares during the last quarter. Finally, Empowered Funds LLC acquired a new stake in shares of Chemours during the first quarter worth $403,000. Institutional investors and hedge funds own 76.26% of the company’s stock.

Key Stories Impacting Chemours

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Zacks raised its FY2027 EPS forecast to $2.05 from $1.95 and increased Q4 2027 EPS to $0.61 from $0.53, suggesting improved profitability may emerge beyond 2026.
• Positive Sentiment: The firm also lifted estimates for Q1 2027 EPS to $0.40 from $0.39, Q3 2027 EPS to $0.58 from $0.56, Q1 2028 EPS to $0.56 from $0.55, and Q2 2028 EPS to $0.65 from $0.61.
• Neutral Sentiment: The revisions indicate a potentially stronger longer-term earnings trajectory, but they are offset by weaker expectations for the company’s immediate results. Zacks’ current full-year EPS consensus is approximately $0.87.
• Negative Sentiment: Zacks cut its FY2026 EPS forecast to $0.83 from $0.90 and reduced Q4 2026 EPS to $0.11 from $0.12, signaling pressure on near-term earnings.
• Negative Sentiment: The largest revision was a reduction in Q3 2026 EPS to $0.25 from $0.41. That forecast implies a substantial decline from the previous estimate and could weigh on investor sentiment.
• Negative Sentiment: FY2028 EPS was also lowered to $2.31 from $2.38, indicating that longer-term optimism is not broad-based. Chemours recently missed quarterly revenue and EPS expectations, adding to concerns about operating momentum.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on CC shares. BMO Capital Markets dropped their target price on Chemours from $26.00 to $18.00 and set an “outperform” rating for the company in a research note on Thursday, August 13th. Mizuho set a $22.00 price target on Chemours in a research note on Wednesday, August 5th. Royal Bank Of Canada lowered their price target on Chemours from $26.00 to $22.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. JPMorgan Chase & Co. dropped their price objective on shares of Chemours from $22.00 to $15.00 and set a “neutral” rating for the company in a research note on Thursday, August 13th. Finally, Alembic Global Advisors reiterated an “overweight” rating and set a $30.00 price objective on shares of Chemours in a report on Wednesday, May 13th. Five research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Chemours has a consensus rating of “Hold” and an average price target of $20.10.

Insider Transactions at Chemours

In other Chemours news, insider Calderon Gerardo Familiar acquired 1,935 shares of the company’s stock in a transaction dated Wednesday, August 12th. The stock was bought at an average price of $15.53 per share, with a total value of $30,050.55. Following the completion of the transaction, the insider directly owned 58,547 shares of the company’s stock, valued at approximately $909,234.91. The trade was a 3.42% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Shane Hostetter bought 3,350 shares of the business’s stock in a transaction dated Thursday, August 6th. The stock was acquired at an average cost of $14.94 per share, for a total transaction of $50,049.00. Following the purchase, the chief financial officer owned 102,698 shares in the company, valued at approximately $1,534,308.12. This trade represents a 3.37% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired 8,663 shares of company stock valued at $130,601 over the last 90 days. Corporate insiders own 0.85% of the company’s stock.

Chemours Stock Performance

Chemours stock opened at $15.96 on Monday. The company has a debt-to-equity ratio of 18.98, a current ratio of 1.66 and a quick ratio of 0.88. The Chemours Company has a 12 month low of $10.44 and a 12 month high of $28.67. The company has a market cap of $2.40 billion, a price-to-earnings ratio of -8.36 and a beta of 1.43. The stock’s 50-day moving average is $18.01 and its 200-day moving average is $20.05.

Chemours (NYSE:CC) last posted its earnings results on Tuesday, August 4th. The specialty chemicals company reported $0.42 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.07). Chemours had a positive return on equity of 60.64% and a negative net margin of 5.00%.The business had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.65 billion. During the same period last year, the company posted ($2.54) EPS. The firm’s revenue for the quarter was down 1.5% compared to the same quarter last year. Equities analysts anticipate that The Chemours Company will post 0.87 earnings per share for the current year.

Chemours Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Friday, August 14th will be paid a dividend of $0.0875 per share. This represents a $0.35 annualized dividend and a yield of 2.2%. The ex-dividend date is Friday, August 14th. Chemours’s payout ratio is currently -18.32%.

Chemours Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.